Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Cara Therapeutics Inc’s stock clocked out at $0.34, down -7.84% from its previous closing price of $0.37. In other words, the price has decreased by -$7.84 from its previous closing price. On the day, 0.91 million shares were traded. CARA stock price reached its highest trading level at $0.3898 during the session, while it also had its lowest trading level at $0.34.
Ratios:
To gain a deeper understanding of CARA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.20 and its Current Ratio is at 5.38. In the meantime, Its Debt-to-Equity ratio is 1.52 whereas as Long-Term Debt/Eq ratio is at 1.52.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Stifel on June 13, 2024, Downgraded its rating to Hold and sets its target price to $1 from $6 previously.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 02 ’24 when Posner Christopher sold 3,936 shares for $0.75 per share. The transaction valued at 2,952 led to the insider holds 176,585 shares of the business.
Terrillion Scott sold 2,753 shares of CARA for $2,285 on Apr 05 ’24. The SEC’Y; CHIEF COMPLIANCE & G.C. now owns 88,247 shares after completing the transaction at $0.83 per share. On Apr 05 ’24, another insider, Goncalves Joana, who serves as the CHIEF MEDICAL OFFICER of the company, sold 2,753 shares for $0.83 each. As a result, the insider received 2,285 and left with 53,365 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CARA now has a Market Capitalization of 20024576 and an Enterprise Value of -44083500. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.10 while its Price-to-Book (P/B) ratio in mrq is 0.63. Its current Enterprise Value per Revenue stands at -2.603 whereas that against EBITDA is 0.365.
Stock Price History:
The Beta on a monthly basis for CARA is 0.76, which has changed by -0.8832192 over the last 52 weeks, in comparison to a change of 0.23228896 over the same period for the S&P500. Over the past 52 weeks, CARA has reached a high of $3.45, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is -35.93%, while the 200-Day Moving Average is calculated to be -58.63%.
Shares Statistics:
It appears that CARA traded 865.51K shares on average per day over the past three months and 1482380 shares per day over the past ten days. A total of 54.48M shares are outstanding, with a floating share count of 45.58M. Insiders hold about 16.63% of the company’s shares, while institutions hold 40.85% stake in the company. Shares short for CARA as of 1719532800 were 1927481 with a Short Ratio of 2.23, compared to 1717113600 on 2299704. Therefore, it implies a Short% of Shares Outstanding of 1927481 and a Short% of Float of 4.099999700000001.
